MX2020012980A - Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. - Google Patents
Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.Info
- Publication number
- MX2020012980A MX2020012980A MX2020012980A MX2020012980A MX2020012980A MX 2020012980 A MX2020012980 A MX 2020012980A MX 2020012980 A MX2020012980 A MX 2020012980A MX 2020012980 A MX2020012980 A MX 2020012980A MX 2020012980 A MX2020012980 A MX 2020012980A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- plasma exposure
- tetrahydrobiopterin
- increasing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 title 1
- 229960004617 sapropterin Drugs 0.000 title 1
- VPVOXUSPXFPWBN-UHFFFAOYSA-N L-sepiapterin Natural products N1=C(N)NC(=O)C2=C1NCC(C(=O)C(O)C)=N2 VPVOXUSPXFPWBN-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- VPVOXUSPXFPWBN-VKHMYHEASA-N sepiapterin Chemical compound N1C(N)=NC(=O)C2=C1NCC(C(=O)[C@@H](O)C)=N2 VPVOXUSPXFPWBN-VKHMYHEASA-N 0.000 abstract 1
- 229940126478 sepiapterin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677926P | 2018-05-30 | 2018-05-30 | |
| US201862771397P | 2018-11-26 | 2018-11-26 | |
| US201962822365P | 2019-03-22 | 2019-03-22 | |
| GC201937662 | 2019-05-28 | ||
| PCT/US2019/034515 WO2019232126A1 (en) | 2018-05-30 | 2019-05-30 | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012980A true MX2020012980A (es) | 2021-04-29 |
Family
ID=68699016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012980A MX2020012980A (es) | 2018-05-30 | 2019-05-30 | Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. |
Country Status (22)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| WO2018102315A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymoprhs of sepiapterin and salts thereof |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| CA3102105A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| JP7778477B2 (ja) | 2018-05-30 | 2025-12-02 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| JP7502197B2 (ja) * | 2018-05-30 | 2024-06-18 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリン血漿曝露を増加させるための方法 |
| LT4009978T (lt) | 2019-08-05 | 2024-11-25 | Ptc Therapeutics Mp, Inc. | Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui |
| CA3165636A1 (en) * | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| US12691119B2 (en) | 2021-02-09 | 2026-07-28 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| US12298026B1 (en) | 2021-04-12 | 2025-05-13 | W. L. Gore & Associates, Inc. | Latent energy transfer laminate for plate pack core |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| WO1997007236A1 (en) | 1995-08-18 | 1997-02-27 | Landry Donald W | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| WO2005048926A2 (en) | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
| CA2545968C (en) | 2003-11-17 | 2010-03-09 | Merck Eprova Ag | Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| PT3138566T (pt) | 2003-11-17 | 2022-02-02 | Biomarin Pharm Inc | Tratamento de fenilcetonúria com bh4 |
| CN101132776A (zh) | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| US20100130500A1 (en) | 2004-12-08 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2006118322A1 (en) | 2005-04-28 | 2006-11-09 | Shiratori Pharmaceutical Co., Ltd. | Method for producing hydrazone derivatives |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| KR20160065998A (ko) * | 2007-04-11 | 2016-06-09 | 바이오마린 파머수티컬 인크. | 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법 |
| WO2010017570A2 (de) | 2008-08-12 | 2010-02-18 | Orpha Swiss Gmbh | Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin |
| JP5066756B2 (ja) * | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CA2828685C (en) * | 2011-03-01 | 2018-05-29 | Rubicon Research Private Limited | Stable compositions of tetrahydrobiopterin |
| US9216178B2 (en) * | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| JP6084967B2 (ja) | 2012-05-07 | 2017-02-22 | 白鳥製薬株式会社 | セピアプテリン及びテトラヒドロラクトイルプテリンの製造法 |
| EP3213062B1 (en) | 2014-10-31 | 2020-02-12 | Children's Medical Center Corporation | Methods and assays relating to sepiapterin reductase inhibition |
| WO2018102315A1 (en) * | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymoprhs of sepiapterin and salts thereof |
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| MX2020002271A (es) * | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| JP7778477B2 (ja) * | 2018-05-30 | 2025-12-02 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| CA3102105A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| JP7502197B2 (ja) | 2018-05-30 | 2024-06-18 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリン血漿曝露を増加させるための方法 |
| LT4009978T (lt) | 2019-08-05 | 2024-11-25 | Ptc Therapeutics Mp, Inc. | Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
-
2019
- 2019-05-30 CA CA3102105A patent/CA3102105A1/en active Pending
- 2019-05-30 DK DK19810058.8T patent/DK3801534T3/da active
- 2019-05-30 ES ES19810058T patent/ES3068414T3/es active Active
- 2019-05-30 JP JP2020566737A patent/JP7547215B2/ja active Active
- 2019-05-30 SI SI201931036T patent/SI3801534T1/sl unknown
- 2019-05-30 BR BR112020024329-9A patent/BR112020024329A2/pt active Search and Examination
- 2019-05-30 MD MDE20210331T patent/MD3801534T2/en unknown
- 2019-05-30 MX MX2020012980A patent/MX2020012980A/es unknown
- 2019-05-30 WO PCT/US2019/034515 patent/WO2019232126A1/en not_active Ceased
- 2019-05-30 RS RS20260326A patent/RS68045B1/sr unknown
- 2019-05-30 CN CN201980050730.3A patent/CN112654356A/zh active Pending
- 2019-05-30 PT PT198100588T patent/PT3801534T/pt unknown
- 2019-05-30 SM SM20260220T patent/SMT202600220T1/it unknown
- 2019-05-30 EP EP19810058.8A patent/EP3801534B1/en active Active
- 2019-05-30 EP EP26157861.1A patent/EP4748370A3/en active Pending
- 2019-05-30 US US17/059,632 patent/US12257252B2/en active Active
- 2019-05-30 HR HRP20260360TT patent/HRP20260360T1/hr unknown
- 2019-05-30 PL PL19810058.8T patent/PL3801534T3/pl unknown
- 2019-05-30 FI FIEP19810058.8T patent/FI3801534T3/fi active
- 2019-05-30 LT LTEPPCT/US2019/034515T patent/LT3801534T/lt unknown
-
2024
- 2024-08-28 JP JP2024146283A patent/JP7855033B2/ja active Active
-
2025
- 2025-03-04 US US19/070,026 patent/US20250195529A1/en active Pending
-
2026
- 2026-05-18 NL NL301382C patent/NL301382I2/nl unknown
- 2026-05-20 LT LTPA2026521C patent/LTPA2026521I1/lt unknown
- 2026-05-28 FR FR26C1028C patent/FR26C1028I1/fr active Active
- 2026-05-29 NO NO2026028C patent/NO2026028I1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3102105A1 (en) | 2019-12-05 |
| EP4748370A2 (en) | 2026-05-27 |
| PL3801534T3 (pl) | 2026-07-06 |
| FR26C1028I1 (fr) | 2026-07-17 |
| JP7547215B2 (ja) | 2024-09-09 |
| JP2021525746A (ja) | 2021-09-27 |
| EP4748370A3 (en) | 2026-07-29 |
| ES3068414T3 (en) | 2026-05-29 |
| EP3801534A1 (en) | 2021-04-14 |
| SMT202600220T1 (it) | 2026-07-16 |
| JP7855033B2 (ja) | 2026-05-07 |
| US20210161901A1 (en) | 2021-06-03 |
| SI3801534T1 (sl) | 2026-06-30 |
| LTPA2026521I1 (cg-RX-API-DMAC10.html) | 2026-06-10 |
| US20250195529A1 (en) | 2025-06-19 |
| JP2024178188A (ja) | 2024-12-24 |
| NO2026028I1 (no) | 2026-05-29 |
| CN112654356A (zh) | 2021-04-13 |
| FI3801534T3 (fi) | 2026-04-14 |
| LT3801534T (lt) | 2026-05-25 |
| NL301382I2 (nl) | 2026-07-16 |
| EP3801534B1 (en) | 2026-02-18 |
| MD3801534T2 (en) | 2026-07-31 |
| US12257252B2 (en) | 2025-03-25 |
| EP3801534A4 (en) | 2022-03-16 |
| WO2019232126A1 (en) | 2019-12-05 |
| RS68045B1 (sr) | 2026-05-29 |
| HRP20260360T1 (hr) | 2026-06-05 |
| DK3801534T3 (da) | 2026-03-30 |
| BR112020024329A2 (pt) | 2021-02-23 |
| PT3801534T (pt) | 2026-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005935A (es) | Metodos para aumentar la exposicion al plasma de sepiapterina. | |
| MX2025003987A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos | |
| MX2020002271A (es) | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| MY205416A (en) | Tyk2 inhibitors and uses thereof | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2019013072A (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. | |
| MX376465B (es) | Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret. | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| EA201890318A1 (ru) | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
| EP4454712A3 (en) | Use of sepiapterin and metabolites thereof to treat radiation exposure | |
| MX2017001656A (es) | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| PH12021550413A1 (en) | Vitamin d pediatric dosage forms, methods of making and using | |
| JOP20210305A1 (ar) | صيغ إيماتينيب وتصنيعها واستخداماتها | |
| MX388026B (es) | Compuestos y métodos para modular la tirosina cinasa de bruton. | |
| MX2023014145A (es) | Oligonucleotidos modificados y metodos de uso. | |
| MX2020013352A (es) | Tratamiento para migrañas. | |
| PT3801534T (pt) | Tratamento de fenilcetonúria com sepiapterina | |
| MX2019011116A (es) | Inhibidores de la tirosina quinasa de bruton. | |
| MX2023013844A (es) | Metodos para tratar trastornos mieloproliferativos. | |
| WO2018094106A3 (en) | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES | |
| GEP20196984B (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder |